Pacira Pharmaceuticals (NASDAQ:PCRX) : The most positive equity analysts on Pacira Pharmaceuticals (NASDAQ:PCRX) expects the shares to touch $105, whereas, the least positive believes that the stock will trade at $59 in the short term. The company is covered by 8 Wall Street Brokerage Firms. The average price target for shares are $78.13 with an expected fluctuation of $14.49 from the mean.
Pacira Pharmaceuticals, Inc. has lost 15.65% in the last five trading days and dropped 28.75% in the last 4 weeks. Pacira Pharmaceuticals, Inc. has dropped 37.93% during the last 3-month period . Year-to-Date the stock performance stands at -56.08%. Also, Mizuho Securities initiates coverage on Pacira Pharmaceuticals (NASDAQ:PCRX). The rating major has initiated the coverage with buy rating on the shares. The rating by the firm was issued on April 19, 2016.
Pacira Pharmaceuticals (NASDAQ:PCRX) : The consensus on Pacira Pharmaceuticals (NASDAQ:PCRX) based on 8 analyst recommendation on the company stock is 1.25, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 7 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Pacira Pharmaceuticals (NASDAQ:PCRX): The stock opened at $38.05 on Thursday but the bulls could not build on the opening and the stock topped out at $38.33 for the day. The stock traded down to $31.08 during the day, due to lack of any buying support eventually closed down at $33.73 with a loss of -11.26% for the day. The stock had closed at $38.01 on the previous day. The total traded volume was 3,174,821 shares.
In an insider trading activity,The director of Pacira Pharmaceuticals, Inc., Brege Laura sold 1,000 shares at $46.95 on June 6, 2016. The Insider selling transaction had a total value worth of $46,950. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the companys lead product candidate, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Companys other product candidates include DepoMeloxicam and DepoTranexamic Acid.